Cargando…
Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in precli...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520681/ https://www.ncbi.nlm.nih.gov/pubmed/30986995 http://dx.doi.org/10.3390/cancers11040464 |
_version_ | 1783418786435563520 |
---|---|
author | Boydell, Emma Marinari, Eliana Migliorini, Denis Dietrich, Pierre-Yves Patrikidou, Anna Dutoit, Valérie |
author_facet | Boydell, Emma Marinari, Eliana Migliorini, Denis Dietrich, Pierre-Yves Patrikidou, Anna Dutoit, Valérie |
author_sort | Boydell, Emma |
collection | PubMed |
description | Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in preclinical studies of glioma and in other tumour entities. Here, we conducted a post-hoc exploratory study to evaluate the effect of the IMA950/poly-ICLC peptide vaccine on subsequent BEV administration in high-grade glioma patients. 16 IMA950-vaccinated and 40 non-vaccinated patients were included. At initial diagnosis, patients benefited from surgery and chemoradiation. At first or subsequent recurrence, patients received 10mg/kg of BEV every 2–3 weeks. Primary endpoints were overall survival (OS) and progression-free survival (PFS) from BEV initiation. IMA950-vaccinated patients did not show improved response to BEV as compared to non-vaccinated patients: there was no difference in median PFS (2.6 vs. 4.2 months for vaccinated and control patients, respectively, p = 0.50) nor in median OS (7.8 vs. 10.0 months for vaccinated and control patients, respectively, p = 0.69). In conclusion, potential synergy of BEV and therapeutic vaccines, when administered sequentially, has yet to be established in the clinical setting of GBM recurrence. Potential synergy of concomitant administration should be tested in future trials. |
format | Online Article Text |
id | pubmed-6520681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65206812019-05-31 Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients Boydell, Emma Marinari, Eliana Migliorini, Denis Dietrich, Pierre-Yves Patrikidou, Anna Dutoit, Valérie Cancers (Basel) Article Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in preclinical studies of glioma and in other tumour entities. Here, we conducted a post-hoc exploratory study to evaluate the effect of the IMA950/poly-ICLC peptide vaccine on subsequent BEV administration in high-grade glioma patients. 16 IMA950-vaccinated and 40 non-vaccinated patients were included. At initial diagnosis, patients benefited from surgery and chemoradiation. At first or subsequent recurrence, patients received 10mg/kg of BEV every 2–3 weeks. Primary endpoints were overall survival (OS) and progression-free survival (PFS) from BEV initiation. IMA950-vaccinated patients did not show improved response to BEV as compared to non-vaccinated patients: there was no difference in median PFS (2.6 vs. 4.2 months for vaccinated and control patients, respectively, p = 0.50) nor in median OS (7.8 vs. 10.0 months for vaccinated and control patients, respectively, p = 0.69). In conclusion, potential synergy of BEV and therapeutic vaccines, when administered sequentially, has yet to be established in the clinical setting of GBM recurrence. Potential synergy of concomitant administration should be tested in future trials. MDPI 2019-04-02 /pmc/articles/PMC6520681/ /pubmed/30986995 http://dx.doi.org/10.3390/cancers11040464 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Boydell, Emma Marinari, Eliana Migliorini, Denis Dietrich, Pierre-Yves Patrikidou, Anna Dutoit, Valérie Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients |
title | Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients |
title_full | Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients |
title_fullStr | Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients |
title_full_unstemmed | Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients |
title_short | Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients |
title_sort | exploratory study of the effect of ima950/poly-iclc vaccination on response to bevacizumab in relapsing high-grade glioma patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520681/ https://www.ncbi.nlm.nih.gov/pubmed/30986995 http://dx.doi.org/10.3390/cancers11040464 |
work_keys_str_mv | AT boydellemma exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients AT marinarieliana exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients AT migliorinidenis exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients AT dietrichpierreyves exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients AT patrikidouanna exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients AT dutoitvalerie exploratorystudyoftheeffectofima950polyiclcvaccinationonresponsetobevacizumabinrelapsinghighgradegliomapatients |